Summary
Type B Niemann-Pick disease (NPD) is a nonneuronopathic lysosomal storage disorder which is characterized by accumulation of sphingomyelin-laden macrophages. The availability of plasma markers for storage cells may be of great value in facilitating therapeutic decisions. Given the similarity of the storage cells in NPD and Gaucher disease, we studied Gaucher plasma markers (chitotriosidase and CCL18) in two siblings homozygous for the R228C mutation in acid sphingomyelinase (ASM) and a type B course of NPD. The older sibling, first examined at the age of 9 months, showed marked hepatosplenomegaly and pulmonary involvement. The younger sibling has mild asymptomatic hepatosplenomgaly at the age of 5 months. Analysis of plasma specimens revealed markedly increased levels of chitotriosidase and CCL18 in the older sibling. In the younger child also, plasma chitotriosidase and CCL18 were clearly elevated above normal values almost immediately after birth and rapidly increased further. Histochemistry confirmed production of CCL18 by foam cells. In conclusion, plasma chitotriosidase and CCL18 may also serve as markers for the formation of pathological lipid-laden macrophages in type B NPD, in analogy to Gaucher disease. The availability of sensitive plasma surrogate markers may be of great value for monitoring the efficacy of enzyme supplementation therapy that is currently being developed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aerts JM, Hollak C, Boot R, Groener A (2003) Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 358(1433): 905–914.
Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278(42): 40911–40916.
Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324(21): 1464–1470.
Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM (1995) Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 270(44): 26252–26256.
Boot RG, Renkema GH, Verhoek M, et al (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273(40): 25680–25685.
Boot RG, van Achterberg TA, van Aken BE, et al (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 19(3): 687–694.
Boot RG, Verhoek M, de Fost M, et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103(1): 33–39.
de Groot PG, Strijland A, Kalsbeek R, et al (1980) Effect of 2-deoxyglucose on lysosomal enzymes in cultured human skin fibroblasts. Exp Cell Res 126(1): 207–216.
den Tandt WR, van Hoof F (1996) Marked increase of methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase activity in plasma from Gaucher disease patients. J Inherit Metab Dis 19(3): 344–350.
Guo Y, He W, Boer AM, et al (1995) Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 18(6): 717–722.
Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93(3): 1288–1292.
Hollak CE, Maas M, Aerts JM (2001) Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 24 (supplement 2): 97–105.
Miranda SR, He X, Simonaro CM, et al (2000) Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J 14(13): 1988–1995.
Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM (2000) Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96: 1969–1978.
Quintern LE, Schuchman EH, Levran O, et al (1989) Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. EMBO J 8: 2469–2473.
Schuchman EH, Desnick RJ (1995) Niemann-Pick disease types A and B: acid sphinogmyelinase deficiencies. The Metabolic Basis of Inherited Disease, 3589–3610.
Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH (2002) The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet 71: 1413–1419.
Vanier MT (1983) Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta 750: 178–184.
vom Dahl S, Harzer K, Rolfs A, et al (1997) Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase-1 exon 8 splice junction mutation. J Hepatol 31(4): 741–746.
Zhou H, Linke RP, Schaefer HE, Mobius W, Pfeifer U (1995) Progressive liver failure in a patient with adult Niemann-Pick disease associated with generalized AL amyloidosis. Virchows Arch 426: 635–639.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brinkman, J., Wijburg, F.A., Hollak, C.E. et al. Plasma chitotriosidase and CCL18: Early biochemical surrogate markers in type B Niemann-Pick disease. J Inherit Metab Dis 28, 13–20 (2005). https://doi.org/10.1007/s10545-005-4416-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10545-005-4416-9